{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ivosidenib+%28AG-120%29&page=2",
    "query": {
      "intervention": "ivosidenib (AG-120)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 43,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ivosidenib+%28AG-120%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ivosidenib+%28AG-120%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T19:07:24.895Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02074839",
      "title": "Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Acute Myeloid Leukemia (AML)",
        "Untreated AML",
        "Other IDH1-mutated Positive Hematologic Malignancies",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "AG-120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institut de Recherches Internationales Servier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 291,
      "start_date": "2014-03-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-09T19:07:24.895Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02074839"
    },
    {
      "nct_id": "NCT03282513",
      "title": "A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "AG-120 (Ivosidenib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 33,
      "start_date": "2017-09-26",
      "completion_date": "2018-03-31",
      "has_results": false,
      "last_update_posted_date": "2018-04-27",
      "last_synced_at": "2026-10-09T19:07:24.895Z",
      "location_count": 2,
      "location_summary": "Lakewood, Colorado • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03282513"
    },
    {
      "nct_id": "NCT04955938",
      "title": "A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "IDH Mutation",
        "IDH1 Mutation",
        "IDH2 Gene Mutation",
        "Blood Cancer",
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "Ivosidenib",
          "type": "DRUG"
        },
        {
          "name": "Enasidenib",
          "type": "DRUG"
        },
        {
          "name": "Fedratinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-10-29",
      "completion_date": "2023-06-07",
      "has_results": false,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-10-09T19:07:24.895Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04955938"
    },
    {
      "nct_id": "NCT03173248",
      "title": "Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Newly Diagnosed Acute Myeloid Leukemia (AML)",
        "Untreated AML",
        "AML Arising From Myelodysplastic Syndrome (MDS)",
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "AG-120",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institut de Recherches Internationales Servier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2017-06-26",
      "completion_date": "2026-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-10-09T19:07:24.895Z",
      "location_count": 2,
      "location_summary": "Louisville, Kentucky • Boston, Massachusetts",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03173248"
    },
    {
      "nct_id": "NCT03343197",
      "title": "Study of AG-120 and AG-881 in Subjects With Low Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "AG-120",
          "type": "DRUG"
        },
        {
          "name": "AG881",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institut de Recherches Internationales Servier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2018-03-20",
      "completion_date": "2025-03-28",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-10-09T19:07:24.895Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03343197"
    },
    {
      "nct_id": "NCT07006688",
      "title": "A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "IDH1-Mutated Malignancies"
      ],
      "interventions": [
        {
          "name": "Ivosidenib Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Servier Bio-Innovation LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-01-14",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-09T19:07:24.895Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Columbus, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07006688"
    },
    {
      "nct_id": "NCT02632708",
      "title": "Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Newly Diagnosed Acute Myeloid Leukemia (AML)",
        "Untreated AML",
        "AML Arising From Myelodysplastic Syndrome (MDS)",
        "AML Arising From Antecedent Hematologic Disorder (AHD)",
        "AML Arising After Exposure to Genotoxic Injury"
      ],
      "interventions": [
        {
          "name": "AG-120",
          "type": "DRUG"
        },
        {
          "name": "AG-221",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "idarubicin",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institut de Recherches Internationales Servier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2015-12-31",
      "completion_date": "2026-07-24",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-09T19:07:24.895Z",
      "location_count": 14,
      "location_summary": "Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02632708"
    },
    {
      "nct_id": "NCT07392242",
      "title": "A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Ivosidenib",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2026-01-27",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-09T19:07:24.895Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07392242"
    },
    {
      "nct_id": "NCT03680677",
      "title": "Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leukemia, Acute",
        "MDS"
      ],
      "interventions": [
        {
          "name": "Bone Marrow or Peripheral Blood Graft (BMT)",
          "type": "PROCEDURE"
        },
        {
          "name": "Cancer-directed Therapy or Best Supportive Care",
          "type": "OTHER"
        },
        {
          "name": "Frailty Assessment",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-09-21",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-09T19:07:24.895Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03680677"
    },
    {
      "nct_id": "NCT06501625",
      "title": "Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation"
      ],
      "interventions": [
        {
          "name": "Ivosidenib",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab (for the first 8, 21-day, cycles)",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine (for the first 8, 21-day, cycles)",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin (for the first 8, 21-day, cycles)",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab (starting from cycle 9)",
          "type": "DRUG"
        },
        {
          "name": "Ivosidenib Recommended Combination Dose (RCD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institut de Recherches Internationales Servier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2024-12-16",
      "completion_date": "2027-09-13",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-10-09T19:07:24.895Z",
      "location_count": 8,
      "location_summary": "Los Alamitos, California • Los Angeles, California • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06501625"
    }
  ]
}